Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Design Therapeutics, Inc.DSGN · Entity 4991 | Director | May 31, 2023 | June 02, 2023 |
| NextCure, Inc.NXTC · Entity 7461 | Director | June 24, 2021 | June 28, 2021 |
| Tempest Therapeutics, Inc.TPST · Entity 7734 | Director | July 01, 2021 | September 21, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Design Therapeutics, Inc.
Report date May 31, 2023 · Filed June 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.63 · Expires 2033-05-30 | Direct | 15,000 |
Reported balance
After 2023-05-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-31 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to the option vest in equal monthly installments over 12 months following May 31, 2023 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option vest in equal monthly installments over 12 months following May 31, 2023 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders.
NextCure, Inc.
Report date June 24, 2021 · Filed June 28, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.21 · Expires 2031-06-23 | Direct | 14,250 |
Reported balance
After 2021-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-24 · Grant · Acquired 14,250 · Balance 14,250 F1: The option vests in full on the earlier of June 24, 2022 and the date of the 2022 Annual Meeting of Stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of June 24, 2022 and the date of the 2022 Annual Meeting of Stockholders.
Tempest Therapeutics, Inc.
Report date July 01, 2021 · Filed September 21, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.07 · Expires 2031-06-30 | Direct | 6,635 |
Reported balance
After 2021-07-01 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-07-01 · Grant · Acquired 6,635 · Balance 6,635 F1: Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. F2: The reporting person holds these securities for the benefit of Quan Venture Fund I, L.P. ("Quan Capital"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The reporting person is amanager of Quan Venture Partners I, L.L.C. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest. This report on Form 4 shall not be deemed anadmission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.
F2: The reporting person holds these securities for the benefit of Quan Venture Fund I, L.P. ("Quan Capital"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The reporting person is amanager of Quan Venture Partners I, L.L.C. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest. This report on Form 4 shall not be deemed anadmission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
ARMO BioSciences, Inc.
Report date June 22, 2018 · Filed June 22, 2018
Section 16 reporting ended · disclosed 2018-06-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Quan Venture Fund I, L.P. | 0 |
Reported balance
After 2018-06-22 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2018-06-22 · Other · Disposed 404,900 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F4: These Shares are held of record held by Quan Venture Fund I, L.P. ("Quan Capital"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The Reporting Person is a manager of Quan Venture Partners I, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Capital. The Reporting Person disclaims beneficial ownership of the shares held by Quan Capital, except to the extent of her pecuniary interest. F5: Each of Quan Capital and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.97 · Expires 2028-03-25 | Direct | 0 |
Reported balance
After 2018-06-22 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-06-22 · Disposition to issuer · Disposed 18,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share.
F2: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option.
F3: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above.
F4: These Shares are held of record held by Quan Venture Fund I, L.P. ("Quan Capital"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The Reporting Person is a manager of Quan Venture Partners I, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Capital. The Reporting Person disclaims beneficial ownership of the shares held by Quan Capital, except to the extent of her pecuniary interest.
F5: Each of Quan Capital and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 31, 2023 Filed Jun 2, 2023 20:31 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $5.63 | $0.00 |
DisclosureSEC source: 0001209191-23-033785 · doc4.xml · derivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following May 31, 2023 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| June 15, 2022 Filed Jun 16, 2022 21:17 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0001209191-22-037525 · doc4.xml · derivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-06-14 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over 12 months following June 15, 2022 provided that the shares subject to the option will in any case be fully vested on the date of the Company's next annual meeting of stockholders. Read SEC document |
| March 22, 2022 Filed Mar 22, 2022 23:26 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | SaleCommon Stock | 1,455 | $18.63 | $27,105.49 |
DisclosureSEC source: 0001209191-22-020637 · doc4.xml · nonDerivative · entry 4 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,129,950 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.51 to $18.835, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. F2 · ownership.nature: The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 23:26 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | SaleCommon Stock | 24,000 | $19.01 | $456,240.00 |
DisclosureSEC source: 0001209191-22-020637 · doc4.xml · nonDerivative · entry 3 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,131,405 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.30, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. F2 · ownership.nature: The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 23:26 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | SaleCommon Stock | 13,200 | $20.34 | $268,488.00 |
DisclosureSEC source: 0001209191-22-020637 · doc4.xml · nonDerivative · entry 2 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,155,405 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.70, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. F2 · ownership.nature: The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 23:26 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | SaleCommon Stock | 552,225 | $19.04 | $10,514,364.00 |
DisclosureSEC source: 0001209191-22-020637 · doc4.xml · nonDerivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,168,605 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.8726, inclusive. The Reporting Person undertakes to provide the Issuer, and security holder of the Issuer, or the staff at the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth herein. F2 · ownership.nature: The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 22:05 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 6,635 | Not disclosed Strike: $11.07 | Not disclosed |
DisclosureSEC source: 0001140361-21-023544 · form4.xml · derivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,635 Underlying: Common Stock · 6,635 shares Expires 2031-06-30 F1 · price: One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service. F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service. F2 · ownership.direct: The reporting person holds these securities for the benefit of Quan Venture Fund I, L.P. ("Quan Capital"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The reporting person is a manager of Quan Venture Partners I, L.L.C. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest. This report on Form 4 shall not be deemed an admission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| July 01, 2021 Filed Sep 21, 2021 00:10 UTC Amendment | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantStock Option (Right to Buy) · Derivative | 6,635 | $0.00 Strike: $11.07 | $0.00 |
DisclosureSEC source: 0001179110-21-008866 · edgar.xml · derivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,635 Underlying: Common Stock · 6,635 shares Expires 2031-06-30 F1 · derivative.exercise_date: Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date. F2 · ownership.direct: The reporting person holds these securities for the benefit of Quan Venture Fund I, L.P. ("Quan Capital"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The reporting person is amanager of Quan Venture Partners I, L.L.C. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest. This report on Form 4 shall not be deemed anadmission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 25, 2021 Filed Jun 30, 2021 01:56 UTC | Tempest Therapeutics, Inc. TPST · Entity 7734 | GrantCommon Stock | 579,710 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001140361-21-022786 · form4.xml · nonDerivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Quan Venture Fund I, L.P. Disclosed balance after: 579,710 F4 · shares: This amount includes 104,176 shares that were acquired upon conversion of 3,235,294 shares of Tempest, which Quan Capital agreed to purchase at a purchase price of $0.85 per share pursuant to a Funding Agreement with Tempest, which was conditioned upon the satisfaction or waiver of the conditions to Closing. F1 · price: In connection with the merger of Millendo Therapeutics, Inc. ("Millendo") and private company Tempest Therapeutics, Inc. ("Tempest"), pursuant to the Agreement and Plan of Merger dated March 29, 2021 (the "Merger Agreement"), which closed on June 25, 2021 ("Closing"), each share of Tempest's common stock converted into the right to receive approximately 0.0322 shares of Millendo common stock. The Exchange Ratio gives effect to the 15-to-1 reverse stock split of Millendo's common stock. On the Closing date, the closing price of Millendo common stock was $1.06 (unadjusted). Upon Closing, Millendo was renamed "Tempest Therapeutics, Inc." F2 · ownership.nature: These shares are held of record held by Quan Venture Fund I, L.P. ("Quan Capital"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The Reporting Person is a manager of Quan Venture Partners I, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Capital. The Reporting Person disclaims beneficial ownership of the shares held by Quan Capital, except to the extent of any pecuniary interest. F3 · ownership.nature: Each of Quan Capital and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission the Reporting Person is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 22:16 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $8.21 | $0.00 |
DisclosureSEC source: 0001567619-21-012670 · doc1.xml · derivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2031-06-23 F1 · derivative.exercise_date: The option vests in full on the earlier of June 24, 2022 and the date of the 2022 Annual Meeting of Stockholders. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:19 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | ConversionSeries B Preferred Stock · Derivative | 458,016 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-024234 · doc4.xml · derivative · entry 5 Xu Stella · CIK 0001728741 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 280,991 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:19 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | ConversionSeries A Preferred Stock · Derivative | 7,236,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-024234 · doc4.xml · derivative · entry 4 Xu Stella · CIK 0001728741 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 4,439,839 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F1 · derivative.exercise_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F1 · derivative.expiration_date: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:19 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | PurchaseCommon Stock | 10,000 | $20.00 | $200,000.00 |
DisclosureSEC source: 0001209191-21-024234 · doc4.xml · nonDerivative · entry 3 Xu Stella · CIK 0001728741 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 4,730,830 F3 · kind: The shares were purchased in the Issuer's initial public offering. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:19 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | ConversionCommon Stock | 280,991 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-024234 · doc4.xml · nonDerivative · entry 2 Xu Stella · CIK 0001728741 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,720,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 22:19 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | ConversionCommon Stock | 4,439,839 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-024234 · doc4.xml · nonDerivative · entry 1 Xu Stella · CIK 0001728741 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 4,439,839 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F1 · price: All outstanding shares of Preferred Stock automatically converted into shares of Common Stock immediately upon the closing of the Issuer's initial public offering, for no additional consideration at a rate of one share of Common Stock for each 1.63 shares of Preferred Stock, based on the conversion price currently in effect. The Preferred Stock has no expiration date. F2 · ownership.nature: The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P., except to the extent of her pecuniary interest. Read SEC document |
| March 25, 2021 Filed Mar 29, 2021 22:31 UTC | Design Therapeutics, Inc. DSGN · Entity 4991 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001209191-21-023472 · doc4.xml · derivative · entry 1 Xu Stella · CIK 0001728741 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-03-24 F1 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over the 12 months following March 25, 2021. Read SEC document |
| June 11, 2020 Filed Jun 15, 2020 21:47 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 14,250 | $0.00 Strike: $24.13 | $0.00 |
DisclosureSEC source: 0001123292-20-000885 · edgar.xml · derivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,250 Underlying: Common Stock · 14,250 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 and the date of the 2021 Annual Meeting of Stockholders. Read SEC document |
| June 13, 2019 Filed Jun 18, 2019 00:20 UTC | NextCure, Inc. NXTC · Entity 7461 | GrantStock Option (Right to Buy) · Derivative | 22,000 | $0.00 Strike: $15.57 | $0.00 |
DisclosureSEC source: 0001123292-19-000886 · edgar.xml · derivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,000 Underlying: Common Stock · 22,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on June 13, 2020. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:32 UTC | NextCure, Inc. NXTC · Entity 7461 | ConversionSeries B-2 Preferred Stock · Derivative | 7,861,636 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000750 · edgar.xml · derivative · entry 3 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Quan Venture Fund II, L.P. Disclosed balance after: 0 Underlying: Common Stock · 978,570 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.exercise_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F1 · derivative.expiration_date: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:32 UTC | NextCure, Inc. NXTC · Entity 7461 | PurchaseCommon Stock | 125,000 | $15.00 | $1,875,000.00 |
DisclosureSEC source: 0001123292-19-000750 · edgar.xml · nonDerivative · entry 2 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Quan Venture Fund II, L.P. Disclosed balance after: 1,103,570 F2 · ownership.nature: The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P. except to the extent of her pecuniary interest therein. Read SEC document |
| May 13, 2019 Filed May 13, 2019 23:32 UTC | NextCure, Inc. NXTC · Entity 7461 | ConversionCommon Stock | 978,570 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001123292-19-000750 · edgar.xml · nonDerivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Quan Venture Fund II, L.P. Disclosed balance after: 978,570 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The reported securities automatically converted into shares of Common Stock on a 1-for-8.0338 basis upon the closing of the Issuer's initial public offering and had no expiration date. F2 · ownership.nature: The general partner of Quan Venture Fund II, L.P. is Quan Venture Partners II, L.L.C. Stella Xu is a managing director of Quan Venture Partners II, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Venture Fund II, L.P. Dr. Xu disclaims beneficial ownership of the shares held by Quan Venture Fund II, L.P. except to the extent of her pecuniary interest therein. Read SEC document |
| June 22, 2018 Filed Jun 22, 2018 19:34 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | Disposition to issuerStock Option (right to buy) · Derivative | 18,000 | $10.03 Strike: $39.97 | $180,540.00 |
DisclosureSEC source: 0000899243-18-017785 · doc4.xml · derivative · entry 2 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2028-03-25 F2 · shares: Pursuant to the Merger Agreement, each outstanding option to purchase shares of the Issuer's common stock, whether or not exercisable or vested, was cancelled and the holder thereof became entitled to receive an amount in cash determined by multiplying (A) the excess, if any, of $50.00 over the exercise price per share of the common stock underlying such stock option by (B) the number of shares of common stock subject to such stock option. F3 · derivative.exercise_date: This option, which provided for vesting in thirty-six equal monthly installments following March 31, 2018, was cancelled and the Reporting Person became entitled to receive an amount in cash per the terms of the Merger Agreement, as described in footnote (2) above. Read SEC document |
| June 22, 2018 Filed Jun 22, 2018 19:34 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | OtherCommon Stock | 404,900 | $50.00 | $20,245,000.00 |
DisclosureSEC source: 0000899243-18-017785 · doc4.xml · nonDerivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Quan Venture Fund I, L.P. Disclosed balance after: 0 F1 · shares: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated May 9, 2018, by and among the Issuer, Eli Lilly and Company ("Parent") and Bluegill Acquisition Corporation ("Merger Sub"), a wholly-owned subsidiary of Parent, Merger Sub made a cash tender offer (the "Offer") to purchase each outstanding share of the Issuer's common stock for $50.00 per share (the "Offer Price"), net to the seller in cash, without interest and less any applicable tax withholding. These shares were tendered into the Offer and, after the expiration of the Offer at one minute after 11:59 pm Eastern Time on June 21, 2018, Merger Sub accepted all of the tendered shares and the holder was entitled to receive the Offer Price per share. F4 · ownership.nature: These Shares are held of record held by Quan Venture Fund I, L.P. ("Quan Capital"). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The Reporting Person is a manager of Quan Venture Partners I, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Capital. The Reporting Person disclaims beneficial ownership of the shares held by Quan Capital, except to the extent of her pecuniary interest. F5 · ownership.nature: Each of Quan Capital and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| March 26, 2018 Filed Mar 28, 2018 16:56 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $39.97 | $0.00 |
DisclosureSEC source: 0000899243-18-008734 · doc4.xml · derivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-03-25 F1 · derivative.exercise_date: 1/36th of the shares of common stock subject to the option vest on the last day of the calendar month in which the option was granted, and 1/36th of the shares subject to the option vest on the last day of the 35 calendar months immediately thereafter. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 17:09 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | ConversionSeries C-1 Convertible Preferred Stock · Derivative | 404,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-002283 · doc4.xml · derivative · entry 2 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Quan Venture Fund I, L.P. Disclosed balance after: 0 Underlying: Common Stock · 404,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.exercise_date: Each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F2 · derivative.expiration_date: Each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: These Shares are held of record held by Quan Venture Fund I, L.P. (Quan Capital). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The Reporting Person is a manager of Quan Venture Partners I, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Capital. The Reporting Person disclaims beneficial ownership of the shares held by Quan Capital, except to the extent of her pecuniary interest. F4 · ownership.nature: Each of Quan Capital and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
| January 30, 2018 Filed Jan 30, 2018 17:09 UTC | ARMO BioSciences, Inc. ARMO · Entity 12201 | ConversionCommon Stock | 404,900 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-002283 · doc4.xml · nonDerivative · entry 1 Xu Stella · CIK 0001728741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Quan Venture Fund I, L.P. Disclosed balance after: 404,900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The total represents shares received upon conversion of shares of Series C-1 Convertible Preferred Stock. F2 · price: Each share of Series C-1 Convertible Preferred Stock automatically converted into one share of Issuer's Common Stock for no additional consideration immediately prior to the completion of the Issuer's initial public offering. The Convertible Preferred Stock had no expiration date. F3 · ownership.nature: These Shares are held of record held by Quan Venture Fund I, L.P. (Quan Capital). The general partner of Quan Capital is Quan Venture Partners I, L.L.C. The Reporting Person is a manager of Quan Venture Partners I, L.L.C. and shares the ultimate power to vote or dispose of the shares held by Quan Capital. The Reporting Person disclaims beneficial ownership of the shares held by Quan Capital, except to the extent of her pecuniary interest. F4 · ownership.nature: Each of Quan Capital and the Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its or her pecuniary interest therein, if any. This report on Form 4 shall not be deemed an admission that any of the reporting persons is a beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.